Email this article 
Medikamentoznoe lechenie leyomiomy matki antigestagenami: vozmozhnosti i perspektivy
- Authors: Samoylova TE1
-
Affiliations:
- Issue: Vol 13, No 3 (2011)
- Pages: 12-18
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/28153
- ID: 28153
Cite item
Full Text
Abstract
References
- Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Reprod Med 2004; 22: 2.
- Healy DL, Vollenhoven B, Weston G. Uterine fibroids. In: Shaw RW, Soutter WP, Stanton SL eds. Gynecology, Philadelphia. Churchill Livingstone 2003; p. 479-94.
- Azici A, Sozen I. Transforming growth factor - beta-3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000; 73 (5): 1006-11.
- Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002; 99 (2): 229-34.
- Manyonda I, Sinthamoney A-M, Belli E. Controversies and challenges in the modern management of uterine fibroids. Br J Obstet Gynaecol 2004; 111: 95-102.
- Vercellini P, Trespidi L, Zaina B et al. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril 2003; 79: 1390-5.
- Di Lieto A, De Falco M, Pollio F et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005; 12 (2): 123-8.
- Steinauer J, Pritts E, Jackson R et al. Systematic review of Mifepristone for the treatment of uterine leiomyomata. J Obstet Gynecol 2004; 103 (6): 1331-6.
- Young SL, Al-Hendy A. Potential Nonhormonal Therapeutics for Medical Treatment of Leiomyomas. In: Uterine Leiomyomas: Options and Choices. Ed. in Chief B.Carr. Seminars in Reproductive Medicine 2004; 22 (2): 121-30.
- Ganesan, S, Michelle S. Identification and Characterization of Novel Estrogen Reseptor-β-Sparing Antiprogestins. Endocrinology 2002; 143 (8): 3071-82.
- Bodner K, Bodner-Adler B, Kimberger O et al. Bcl-2 receptor expression in patients with uterine smooth muscle tumors. J Soc Gynecol Invest 2004; 11: 187-91.
- Martel KM, Ko AC, Christman GM et al. Apoptosis in Human Uterine Leiomyomas. Semin Reprod Med 2004; 22 (2): 91-102.
- Liang Y, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 2005; 146 (8): 3632-41.
- Ratherford AJ Molecular pharmacology. In: Reproductive Medicine. Molecular, Cellular and Genetic Fundamentals. Ed. O.Bart, M.Fauser, 2003; p. 313-62.
- Poncelet C, Madelanat P, Feldman G et al. Expression of von Willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002; 78: 581-6.
- Smith SK. Angiogenesis and reproduction. Br J Obstet Gynecol 2001; 108: 777-83.
- Степанова Е.В. Антиангиогенная терапия: новые возможности лечения злокачественных заболеваний. Практическая онкология. 2002; 4 (3): 246-52.
- Wu JJ, Richer J, Horwitz KB et al. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res 2004; 64 (6): 2238-44.
- Spitz IM. Progesterone antagonists and progesterone receptor modulators. Expert Opin Investig Drugs 2003; 12 (10): 1693-1707.
- Chwalisz K, DeManno D. Therapeutic potential for the selective progesterone reseptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 2004; 22 (2): 113-9.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).